Short answer
XOMA Royalty Corp (XOMA) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 8.01 (Other Events). XOMA completed Generation Bio acquisition February 9, 2026, adding cash, $98.0M of Section 174 tax deductions, and legacy LNP assets.
XOMA Royalty Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- XOMA completed Generation Bio acquisition February 9, 2026, adding cash, $98.0M of Section 174 tax deductions, and legacy LNP assets
- Tendered shares represented approximately 70% ownership; consideration was $4.2913 cash per share plus one non-tradeable CVR
- XOMA does not plan to advance Generation Bio’s preclinical programs, limiting operating integration but preserving potential asset monetization proceeds
- CVR holders receive proceeds from excess cash, lease recovery, legacy-asset monetization, and Moderna royalties over a 10-year period
- XOMA estimates CVR value at $0.81 per share, excluding highly uncertain legacy assets and Moderna milestone economics
Item 8.01 · Other Events
- XOMA Royalty completed the Merger on February 9, 2026
- Merger completion marks a material corporate milestone for XOMA, XOMAO, and XOMAP stakeholders
- Exhibit 99.1 contains the press release and transaction details relevant to valuation and shareholder implications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other XOMA Royalty Corp 8-K filings
Get the next XOMA 8-K as it lands
Follow XOMA for push alerts, or ask the research agent what this filing means.